Home » Stocks » TLIS

Talis Biomedical Corporation (TLIS)

Stock Price: $14.89 USD -0.65 (-4.18%)
Updated Mar 4, 2021 4:00 PM EST - Market closed
After-hours: $14.74 -0.15 (-1.01%) Mar 4, 7:48 PM
Market Cap 397.05M
Revenue (ttm) 12.21M
Net Income (ttm) -54.57M
Shares Out 53.34M
EPS (ttm) -1.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 4
Last Price $14.89
Previous Close $15.54
Change ($) -0.65
Change (%) -4.18%
Day's Open 15.57
Day's Range 14.25 - 16.20
Day's Volume 322,456
52-Week Range 14.25 - 33.90


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 1 week ago

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented t...

Other stocks mentioned: BMBL, FISV, ATEX, CRVS, DBTX, MTEM, NEXI, ONCR, PRTA
GlobeNewswire - 2 weeks ago

Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular...

GlobeNewswire - 3 weeks ago

Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular...

NASDAQ - 1 month ago

Talis Biomedical, which is developing diagnostic tests for COVID-19 and other infectious diseases, filed on Friday with the SEC to raise up to $150 million in an initial public offering.

SEC - 1 month ago

Talis Biomedical Corporation has filed to go public with an IPO on the NASDAQ.

About TLIS

Talis aims to transform diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases and other conditions at the point-of-care. We are developing the Talis One platform, a sample-to-answer, cloud-enabled molecular diagnostic platform. The Talis One platform comprises a compact instrument, single-use test cartridges and software, including a central cloud database, which work together and are designed to provide central labora... [Read more...]

Medical Devices
IPO Date
Feb 12, 2021
Brian Coe
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2019, TLIS's revenue was $3.98 million, an increase of 66.40% compared to the previous year's $2.39 million. Losses were -$27.47 million, 28.8% more than in 2018.

Financial Statements